For example, in the anidulafungin phase III trial discussed above,46 18% of Olaparib research buy the isolates are non-susceptible according to EUCAST. How these microbiological data should be incorporated into therapeutic decisions remains to be determined, but it may add to the growing reluctance to use of fluconazole upfront in critically ill patients. Factors influencing the physician’s treatment decisions in the ICU are summarised in Table 4.

Echinocandins exhibit several pharmacological features predisposing them for the use in intensive care patients. These include fungicidal action against most Candida spp., generally favourable tolerability; few drug interactions, lack of or moderate dependence on organ function. However, there are some relevant discrepancies (Table 5), largely resulting from divergent modes of metabolisation. Some drug interactions must be considered for caspofungin and micafungin while anidulafungin has not been reported to interact with other substances U0126 to a clinically meaningful extent.54–56 Anidulafungin elimination and thus pharmacokinetics are independent of organ function,54 whereas caspofungin should not be used in patients with severe

liver dysfunction and requires dose reduction in patients with moderate hepatic insufficiency.55 Micafungin may require dose reduction in patients with elevated bilirubin levels (>5 mg dl−1).57 Phosphoprotein phosphatase Reported adverse event rates

tend to be lower in studies with anidulafungin and micafungin, particularly in terms of infusion-related side-effects and fever.58 However, the randomised trial directly comparing micafungin and caspofungin did not show significant differences in the adverse event rates.50 Caspofungin plasma levels were shown to be reduced in surgical intensive care patients with >75 kg body weight, and dose escalation is recommended in patients with >80 kg, while anidulafungin and micafungin do not require dose adjustments for body weight.54–56,59 The independence of the pharmacokinetics from organ function and co-medications may be considered features predisposing anidulafungin for early use in severely ill ICU patients, particularly in cases with liver dysfunction. It should be mentioned that the European Medicines Agency restricted the indication of micafungin to patients with no other therapeutic options as it was shown to cause foci of altered hepatocytes and liver tumours in preclinical experiments.